Spencer Lessans

Hematology/Oncology Fellow | @VUMChealth | Evidence-based medicine • Medical Education • General hematology/oncology | Views are my own.

[Spencer Lessans @SpenceLessansMD]

@TumorBoardTues @CathyEngMD @IntegrityCE #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/hDrH4kl2xV

👉A patient on a zanzalintinib + atezolizumab trial asks what toxicities need close monitoring

🧐Which grade ≥3 AEs were most common in STELLAR-303❓

[Spencer Lessans @SpenceLessansMD]

@TumorBoardTues @CathyEngMD @IntegrityCE #PostTest Q1️⃣ #TumorBoardTuesday
👉����#CME Eval 🔗 https://t.co/2ZabgcRCrI
👉🏽ALL CME🔗 https://t.co/hDrH4kl2xV

➡️58yo man w/MSS/pMMR, RAS/BRAF WT mCRC has POD after FOLFOX/Pani, FOLFIRI/Bev, & TAS-102

🤔Which study Tx regimen improved OS vs regorafenib in STELLAR-303❓